Enveric Biosciences Inc Cash Flow Conversion Efficiency
Enveric Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Enveric Biosciences Inc (ENVB) has a cash flow conversion efficiency ratio of -0.600x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.07 Million) by net assets ($3.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Enveric Biosciences Inc (1994–2024)
Cash flow conversion efficiency of Enveric Biosciences Inc from 1994 to 2024. This chart illustrates how Enveric Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Enveric Biosciences Inc stock quote for real-time trading data and today's change.
Enveric Biosciences Inc Cash Flow Conversion Ratio Explained
Enveric Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Enveric Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enveric Biosciences Inc ranked by their cash flow conversion efficiency. Also see Enveric Biosciences Inc (ENVB) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
International Parkside Products Inc
V:IPD
|
0.368x |
|
FKS Food Sejahtera Tbk PT
JK:AISA
|
0.005x |
|
Vivanco Gruppe AG
F:VG0K
|
0.164x |
|
Brain+ ApS
CO:BRAINP
|
-0.964x |
|
ALGERNON PHARMACEUT. A
F:AGW0
|
N/A |
|
Prima Moda SA
WAR:PMA
|
0.241x |
|
CAT STRATEGIC MET.
F:8CHA
|
-0.016x |
|
XXL Energy Corp
V:XL
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Enveric Biosciences Inc (1994–2024)
The table below shows the annual cash flow conversion efficiency of Enveric Biosciences Inc from 1994 to 2024. Review ENVB free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.59 Million | $-7.73 Million | -4.851x | +32.67% |
| 2023-12-31 | $1.96 Million | $-14.09 Million | -7.204x | -553.65% |
| 2022-12-31 | $15.56 Million | $-17.15 Million | -1.102x | -114.58% |
| 2021-12-31 | $22.31 Million | $-11.46 Million | -0.514x | +54.88% |
| 2020-12-31 | $3.42 Million | $-3.89 Million | -1.139x | -1766.59% |
| 2019-12-31 | $10.62 Million | $-647.86K | -0.061x | +74.42% |
| 2018-12-31 | $10.76 Million | $-2.57 Million | -0.238x | -69.20% |
| 2017-12-31 | $19.45 Million | $-2.74 Million | -0.141x | +39.21% |
| 2016-12-31 | $11.66 Million | $-2.70 Million | -0.232x | +98.37% |
| 2015-12-31 | $258.53K | $-3.67 Million | -14.202x | -227.36% |
| 2014-12-31 | $-3.87K | $-43.16K | 11.151x | +942.64% |
| 2013-12-31 | $-20.23K | $-21.63K | 1.069x | -13.64% |
| 2012-12-31 | $-20.07K | $-24.85K | 1.238x | +118.59% |
| 2011-12-31 | $4.55K | $-30.35K | -6.662x | -911.20% |
| 2010-12-31 | $-49.52K | $-40.67K | 0.821x | -87.28% |
| 2009-12-31 | $-10.07K | $-65.04K | 6.456x | +308.34% |
| 2008-12-31 | $48.47K | $-150.19K | -3.099x | -1562.39% |
| 2007-12-31 | $1.56 Million | $329.93K | 0.212x | +126.08% |
| 2006-12-31 | $376.50K | $-305.91K | -0.812x | -127.19% |
| 2005-12-31 | $717.40K | $-256.57K | -0.358x | -182.95% |
| 2004-12-31 | $797.74K | $343.94K | 0.431x | +262.19% |
| 2003-12-31 | $955.38K | $-253.97K | -0.266x | -546.12% |
| 2002-12-31 | $1.43 Million | $85.14K | 0.060x | +124.76% |
| 2001-12-31 | $1.41 Million | $-339.68K | -0.241x | -372.35% |
| 2000-12-31 | $1.65 Million | $145.84K | 0.088x | +110.20% |
| 1999-12-31 | $768.14K | $-665.38K | -0.866x | -144.90% |
| 1998-12-31 | $-1.55 Million | $-3.00 Million | 1.929x | +179.57% |
| 1997-12-31 | $1.53 Million | $-3.70 Million | -2.424x | -67.69% |
| 1996-12-31 | $3.27 Million | $-4.72 Million | -1.446x | -48.59% |
| 1995-12-31 | $3.70 Million | $-3.60 Million | -0.973x | -70.27% |
| 1994-12-31 | $1.40 Million | $-800.00K | -0.571x | -- |
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage fo… Read more